JPRN-UMIN000014099招募中未知
The evaluation for safety and efficacy of combination therapy of adoptive immune-cell therapy with chemoradiotherapy for locally advanced esophageal cancer - The evaluation for safety and efficacy of combination therapy of adoptive immune-cell therapy with chemoradiotherapy for locally advanced esophageal cancer
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patient with interstitial pneumonia (2)Patient with active autoimmune disease (3)Patient with active heart disease (4)Patient with uncontrolable infectious diseases (5)Patient with serious drug allergy (6)Patient with continuous use of systemic administration of steroids (7)Patient in pregnancy (8)Patient positive for HIV or HTLV-1 (9)Patients who are inadequate to enter this study due to the other reasons by physician's judgments
研究者
相似试验
已完成
不适用
The evaluation for safety and efficacy of combination therapy of adoptive immune-cell therapy with chemoradiotherapy for locally advanced esophageal cancerocally advanced esophageal cancerJPRN-UMIN000017350Gunma University6
招募中
2 期
Evaluation of the safety and efficacy of combination of neostigmine and ketorolac added to reduced local anesthetic mixture dose through medial canthus injection in vitrectomy surgeryAnaesthesiaPACTR202204650206424Research institute of Ophthalmology50
招募中
不适用
Evaluation of efficacy and safety of combinationtherapy with trastuzumab and eribulin for HER2-positive inoperableness or metastatic breast cancerJPRN-UMIN000007113Wakayama Medical University Department of Thoracic and Cardiovascular Surgery35
已完成
4 期
Evaluation on efficacy and safety of a combination therapy of rituximab with bendamustin in the patients with relapsed or resistnat low grade B-cell non-Hodgkin lymphomapatients with relapsed or resistant low grade B-cell non-Hodgkin lymphomaJPRN-UMIN000008638Hiroshima University26
招募中
2 期
Clinical study on VAMHA and MYRHA Tablets in Polycystic ovary syndromeCTRI/2022/12/048147Gynoveda Femtech Pvt. Ltd